Mereo BioPharma Group plc (FRA:MAH0)

Market Cap	278.37M
Revenue (ttm)	426.15K
Net Income (ttm)	-35.43M
Shares Out	n/a
EPS (ttm)	-0.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Average Volume	78
Open	1.640
Previous Close	1.535
Day's Range	1.640 - 1.725
52-Week Range	1.300 - 3.800
Beta	n/a
RSI	61.46
Earnings Date	Mar 26, 2026

About Mereo BioPharma Group

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab, an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for use in the treatment of tumors. The company is also developing Navicixizumab, which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod, a p38 MAP kinase inhibitor that ...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Employees: 36
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: MAH0

Financial Performance

Financial numbers in USD